APO Research
Talk to an analyst

APO RESEARCH · REPORT

Phosphoinositide 3-Kinase (PI3K) Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Outlook and Growth Opportunities 2026

22 December 2025198 pages

Choose your research edition.

Industry ResearchPhosphoinositide 3-Kinase (PI3K) Inhibitors Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Phosphoinositide 3-Kinase (PI3K) Inhibitors Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Phosphoinositide 3-Kinase (PI3K) Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Phosphoinositide 3-Kinase (PI3K) Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Phosphoinositide 3-Kinase (PI3K) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Phosphoinositide 3-Kinase (PI3K) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Phosphoinositide 3-Kinase (PI3K) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Phosphoinositide 3-Kinase (PI3K) Inhibitors market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Phosphoinositide 3-Kinase (PI3K) Inhibitors market include Novartis AG, Bayer AG, Verastem Inc., TG Therapeutics Inc. and Gilead Sciences Inc., among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Phosphoinositide 3-Kinase (PI3K) Inhibitors market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Phosphoinositide 3-Kinase (PI3K) Inhibitors and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Phosphoinositide 3-Kinase (PI3K) Inhibitors revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Phosphoinositide 3-Kinase (PI3K) Inhibitors market.

Phosphoinositide 3-Kinase (PI3K) Inhibitors Segment by Company

Novartis AG

Bayer AG

Verastem Inc.

TG Therapeutics Inc.

Gilead Sciences Inc.

Phosphoinositide 3-Kinase (PI3K) Inhibitors Segment by Type

CLL - Chronic Iymphocytic Ieukemia

FL - Follicular Iymphoma

Other Indications

Phosphoinositide 3-Kinase (PI3K) Inhibitors Segment by Application

Clinic

hospital

Research Institutes and Research Institutions

Other

Phosphoinositide 3-Kinase (PI3K) Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Phosphoinositide 3-Kinase (PI3K) Inhibitors status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Phosphoinositide 3-Kinase (PI3K) Inhibitors key companies, revenue, market share, and recent developments.

3. To split the Phosphoinositide 3-Kinase (PI3K) Inhibitors breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Phosphoinositide 3-Kinase (PI3K) Inhibitors market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Phosphoinositide 3-Kinase (PI3K) Inhibitors significant trends, drivers, influence factors in global and regions.

6. To analyze Phosphoinositide 3-Kinase (PI3K) Inhibitors competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Phosphoinositide 3-Kinase (PI3K) Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Phosphoinositide 3-Kinase (PI3K) Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Phosphoinositide 3-Kinase (PI3K) Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Phosphoinositide 3-Kinase (PI3K) Inhibitors industry.

Chapter 3: Detailed analysis of Phosphoinositide 3-Kinase (PI3K) Inhibitors company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Phosphoinositide 3-Kinase (PI3K) Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Phosphoinositide 3-Kinase (PI3K) Inhibitors in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Phosphoinositide 3-Kinase (PI3K) Inhibitors Industry Trends Table 2. Phosphoinositide 3-Kinase (PI3K) Inhibitors Industry Drivers Table 3. Phosphoinositide 3-Kinase (PI3K) Inhibitors Industry Opportunities and Challenges Table 4. Phosphoinositide 3-Kinase (PI3K) Inhibitors Industry Restraints Table 5. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Revenue Share by Company (2021-2026) Table 7. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Key Company Manufacturing Base & Headquarters Table 9. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Company, Product Type & Application Table 10. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of CLL - Chronic Iymphocytic Ieukemia Table 15. Significant Companies of FL - Follicular Iymphoma Table 16. Significant Companies of Other Indications Table 17. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type (2021-2026) Table 21. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Clinic Table 23. Significant Companies of hospital Table 24. Significant Companies of Research Institutes and Research Institutions Table 25. Significant Companies of Other Table 26. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application (2021-2026) Table 30. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application (2027-2032) Table 31. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Region (2021-2026) Table 34. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Region (2027-2032) Table 36. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Market Share by Country (2021-2026) Table 39. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Market Share by Country (2027-2032) Table 41. Novartis AG Company Information Table 42. Novartis AG Business Overview Table 43. Novartis AG Phosphoinositide 3-Kinase (PI3K) Inhibitors Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Novartis AG Phosphoinositide 3-Kinase (PI3K) Inhibitors Product Portfolio Table 45. Novartis AG Recent Development Table 46. Bayer AG Company Information Table 47. Bayer AG Business Overview Table 48. Bayer AG Phosphoinositide 3-Kinase (PI3K) Inhibitors Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Bayer AG Phosphoinositide 3-Kinase (PI3K) Inhibitors Product Portfolio Table 50. Bayer AG Recent Development Table 51. Verastem Inc. Company Information Table 52. Verastem Inc. Business Overview Table 53. Verastem Inc. Phosphoinositide 3-Kinase (PI3K) Inhibitors Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Verastem Inc. Phosphoinositide 3-Kinase (PI3K) Inhibitors Product Portfolio Table 55. Verastem Inc. Recent Development Table 56. TG Therapeutics Inc. Company Information Table 57. TG Therapeutics Inc. Business Overview Table 58. TG Therapeutics Inc. Phosphoinositide 3-Kinase (PI3K) Inhibitors Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. TG Therapeutics Inc. Phosphoinositide 3-Kinase (PI3K) Inhibitors Product Portfolio Table 60. TG Therapeutics Inc. Recent Development Table 61. Gilead Sciences Inc. Company Information Table 62. Gilead Sciences Inc. Business Overview Table 63. Gilead Sciences Inc. Phosphoinositide 3-Kinase (PI3K) Inhibitors Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Gilead Sciences Inc. Phosphoinositide 3-Kinase (PI3K) Inhibitors Product Portfolio Table 65. Gilead Sciences Inc. Recent Development Table 66. Research Programs/Design for This Report Table 67. Authors List of This Report Table 68. Secondary Sources Table 69. Primary Sources List of Figures Figure 1. Phosphoinositide 3-Kinase (PI3K) Inhibitors Product Image Figure 2. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. CLL - Chronic Iymphocytic Ieukemia Image Figure 8. FL - Follicular Iymphoma Image Figure 9. Other Indications Image Figure 10. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type (2021-2032) Figure 13. Clinic Image Figure 14. hospital Image Figure 15. Research Institutes and Research Institutions Image Figure 16. Other Image Figure 17. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application (2021-2032) Figure 20. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 23. North America Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 29. South America Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • CLL - Chronic Iymphocytic Ieukemia
  • FL - Follicular Iymphoma
  • Other Indications
Applications
  • Clinic
  • hospital
  • Research Institutes and Research Institutions
  • Other
Companies covered
  • Novartis AG
  • Bayer AG
  • Verastem Inc.
  • TG Therapeutics Inc.
  • Gilead Sciences Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Dynamics
  1. 2.1 Phosphoinositide 3-Kinase (PI3K) Inhibitors Industry Trends
  2. 2.2 Phosphoinositide 3-Kinase (PI3K) Inhibitors Industry Drivers
  3. 2.3 Phosphoinositide 3-Kinase (PI3K) Inhibitors Industry Opportunities and Challenges
  4. 2.4 Phosphoinositide 3-Kinase (PI3K) Inhibitors Industry Restraints
3 Phosphoinositide 3-Kinase (PI3K) Inhibitors Market by Company
  1. 3.1 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Company Revenue Ranking in 2025
  2. 3.2 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Revenue by Company (2021-2026)
  3. 3.3 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Company Ranking (2024-2026)
  4. 3.4 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Company Manufacturing Base and Headquarters
  5. 3.5 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Company Product Type and Application
  6. 3.6 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Phosphoinositide 3-Kinase (PI3K) Inhibitors Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Phosphoinositide 3-Kinase (PI3K) Inhibitors Market by Type
  1. 4.1 Phosphoinositide 3-Kinase (PI3K) Inhibitors Type Introduction
  2. 4.1.1 CLL - Chronic Iymphocytic Ieukemia
  3. 4.1.2 FL - Follicular Iymphoma
  4. 4.1.3 Other Indications
  5. 4.2 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value by Type
  6. 4.2.1 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value by Type (2021-2032)
  8. 4.2.3 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type (2021-2032)
5 Phosphoinositide 3-Kinase (PI3K) Inhibitors Market by Application
  1. 5.1 Phosphoinositide 3-Kinase (PI3K) Inhibitors Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 hospital
  4. 5.1.3 Research Institutes and Research Institutions
  5. 5.1.4 Other
  6. 5.2 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value by Application
  7. 5.2.1 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value by Application (2021-2032)
  9. 5.2.3 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application (2021-2032)
6 Phosphoinositide 3-Kinase (PI3K) Inhibitors Regional Value Analysis
  1. 6.1 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value by Region (2021-2032)
  3. 6.2.1 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value by Region: 2021-2026
  4. 6.2.2 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value (2021-2032)
  7. 6.3.2 North America Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value (2021-2032)
  10. 6.4.2 Europe Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value (2021-2032)
  16. 6.6.2 South America Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Country, 2025 VS 2032
7 Phosphoinositide 3-Kinase (PI3K) Inhibitors Country-level Value Analysis
  1. 7.1 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value by Country (2021-2032)
  3. 7.2.1 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value by Country (2021-2026)
  4. 7.2.2 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Phosphoinositide 3-Kinase (PI3K) Inhibitors Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Phosphoinositide 3-Kinase (PI3K) Inhibitors Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Phosphoinositide 3-Kinase (PI3K) Inhibitors Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 Bayer AG
  8. 8.2.1 Bayer AG Company Information
  9. 8.2.2 Bayer AG Business Overview
  10. 8.2.3 Bayer AG Phosphoinositide 3-Kinase (PI3K) Inhibitors Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bayer AG Phosphoinositide 3-Kinase (PI3K) Inhibitors Product Portfolio
  12. 8.2.5 Bayer AG Recent Developments
  13. 8.3 Verastem Inc.
  14. 8.3.1 Verastem Inc. Company Information
  15. 8.3.2 Verastem Inc. Business Overview
  16. 8.3.3 Verastem Inc. Phosphoinositide 3-Kinase (PI3K) Inhibitors Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Verastem Inc. Phosphoinositide 3-Kinase (PI3K) Inhibitors Product Portfolio
  18. 8.3.5 Verastem Inc. Recent Developments
  19. 8.4 TG Therapeutics Inc.
  20. 8.4.1 TG Therapeutics Inc. Company Information
  21. 8.4.2 TG Therapeutics Inc. Business Overview
  22. 8.4.3 TG Therapeutics Inc. Phosphoinositide 3-Kinase (PI3K) Inhibitors Revenue and Gross Margin (2021-2026)
  23. 8.4.4 TG Therapeutics Inc. Phosphoinositide 3-Kinase (PI3K) Inhibitors Product Portfolio
  24. 8.4.5 TG Therapeutics Inc. Recent Developments
  25. 8.5 Gilead Sciences Inc.
  26. 8.5.1 Gilead Sciences Inc. Company Information
  27. 8.5.2 Gilead Sciences Inc. Business Overview
  28. 8.5.3 Gilead Sciences Inc. Phosphoinositide 3-Kinase (PI3K) Inhibitors Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Gilead Sciences Inc. Phosphoinositide 3-Kinase (PI3K) Inhibitors Product Portfolio
  30. 8.5.5 Gilead Sciences Inc. Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst